{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihic62e43t37usbrvn4zl6ekm6qfha7zmrz5vu2wk7g3s5iv2xlsm",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mkzdbfm5d642"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidxwnwxiiuzhfefvjd3ku2ijjlz2z3odaowk7tods72ifrw2elfby"
    },
    "mimeType": "image/jpeg",
    "size": 120042
  },
  "path": "/2026/05/04/china-biotech-pharmaceuticals-supply-chain-regulations/?utm_campaign=rss",
  "publishedAt": "2026-05-04T08:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "First Opinion",
    "Opinions+",
    "biotechnology",
    "drug development",
    "Pharmaceuticals",
    "Policy",
    "STAT+"
  ],
  "textContent": "China is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.",
  "title": "Opinion: STAT+: China’s strict new supply chain regulations could create massive problems for Western biopharma companies",
  "updatedAt": "2026-05-01T21:04:41.000Z"
}